Panacea Biotec Limited has filed its monthly share dematerialization report for March 2026 with stock exchanges and depositories, fulfilling regulatory requirements under SEBI (Depositories and Participants) Regulations, 2018.

No Dematerialization Activity in March 2026

The company reported that no shares were dematerialized during March 2026. This information was communicated to the National Stock Exchange of India Limited, BSE Limited, National Securities Depository Limited (NSDL), and Central Depository Services (India) Limited (CDSL) on April 07, 2026.

Total Dematerialized Share Position

As of March 31, 2026, the total number of dematerialized shares remained unchanged at 6,11,04,526. The distribution across depositories is as follows:

Monthly Movement Analysis

The registrar and transfer agent, Skyline Financial Services Private Limited, provided a detailed comparison of holdings between February 28, 2026, and March 31, 2026:

The data shows internal transfers between the two depositories during March 2026, with NSDL gaining shares while CDSL's holding decreased by a corresponding amount, keeping the total unchanged.

Regulatory Compliance

The submission was made in accordance with Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, and CDSL's Operating Instructions for Issuers. The report was signed by Ankit Jain, General Manager – Legal & Company Secretary, and certified by Skyline Financial Services Private Limited as the company's registrar and transfer agent.

The company has maintained transparency in its dematerialization reporting process, providing detailed breakdowns and third-party certification to ensure accuracy of the submitted data.

Panacea Biotec Limited has successfully obtained relief from a significant tax demand after receiving a rectified assessment order from the Income Tax Department. The company disclosed this development to stock exchanges on April 07, 2026, under regulatory compliance requirements.

Rectification Application Success

The pharmaceutical company had previously faced a tax demand of ₹10.23 crore for Assessment Year 2016-17 following an assessment order dated March 01, 2026, issued by the Deputy Commissioner of Income Tax (DCIT), New Delhi. The original order had disallowed certain expenditures, leading to the substantial demand.

In response, Panacea Biotec filed a rectification application under the Income Tax Act, 1961, to address what the company identified as errors apparent from the record. The application specifically targeted two key issues: double addition of disallowances and the omission of set-off for brought-forward losses.

Assessment Order Details

Financial Impact and Implications

The rectified assessment order has resulted in a positive financial impact for the company. According to the disclosure, the rectification has successfully nullified the entire tax demand for AY 2016-17. The company has stated that it does not foresee any adverse impact on its financial, operational, or other activities arising from this order.

The rectification addressed specific computational errors in the original assessment, including:

• Correction of double addition of disallowances
• Proper set-off of brought-forward losses
• Elimination of errors apparent from the record

Regulatory Compliance

The company made this disclosure pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The announcement was made in continuation of the company's earlier communication dated March 06, 2026, when it had initially informed exchanges about the original demand order.

Ankit Jain, General Manager – Legal & Company Secretary, signed the disclosure documents on behalf of Panacea Biotec Limited. The company has provided comprehensive details as required under SEBI regulations, including the nature of communication received, expected financial implications, and relevant timelines for the assessment year in question.